Article
Multidisciplinary Sciences
Biyun Wang, Tao Sun, Yannan Zhao, Shusen Wang, Jian Zhang, Zhonghua Wang, Yue-E Teng, Li Cai, Min Yan, Xiaojia Wang, Zefei Jiang, Yueyin Pan, Jianfeng Luo, Zhimin Shao, Jiong Wu, Xiaomao Guo, Xichun Hu
Summary: Platinum in combination with gemcitabine is recommended for the treatment of metastatic triple-negative breast cancer. In a randomized controlled trial, nab-paclitaxel/cisplatin was compared with gemcitabine/cisplatin in mTNBC patients. The study found that nab-paclitaxel/cisplatin significantly improved progression-free survival, objective response rate, and overall survival compared to gemcitabine/cisplatin. However, there were higher incidences of neuropathy in the nab-paclitaxel/cisplatin group and thrombocytopenia in the gemcitabine/cisplatin group.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Kim R. M. Blenman, Michal Marczyk, Thomas Karn, Tao Qing, Xiaotong Li, Vignesh Gunasekharan, Vesal Yaghoobi, Yalai Bai, Eiman Y. Ibrahim, Tristen Park, Andrea Silber, Denise M. Wolf, Emily Reisenbichler, Carsten Denkert, Bruno V. Sinn, Mariya Rozenblit, Julia Foldi, David L. Rimm, Sibylle Loibl, Lajos Pusztai
Summary: This study examined gene expression, germline variant, and somatic mutation features associated with pathologic response to neoadjuvant durvalumab plus chemotherapy in basal-like triple-negative breast cancer. The results showed differences in gene expression and pathway enrichment between cases with different pathologic responses, with immune-rich cases being associated with macrophages, activated B cells, and T cells, while immune-poor cases were associated with other signaling pathways. The findings contribute to a better understanding and prediction of the efficacy of this treatment regimen.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paolo Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Giuseppe Curigliano, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli, Giovanni Scambia
Summary: The ANASTASE study retrospectively analyzed data from PD-L1-positive mTNBC patients treated with atezolizumab plus nab-paclitaxel and found similar results in terms of PFS and ORR as reported in the IMpassion130 study, with no unexpected adverse events.
Article
Oncology
Leisha A. Emens, Luciana Molinero, Sherene Loi, Hope S. Rugo, Andreas Schneeweiss, Veronique Dieras, Hiroji Iwata, Carlos H. Barrios, Marina Nechaeva, Anh Nguyen-Duc, Stephen Y. Chui, Amreen Husain, Eric P. Winer, Sylvia Adams, Peter Schmid
Summary: Understanding the impact of tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors in metastatic triple-negative breast cancer may help optimize patient and treatment selection. The study found that PD-L1 expression and CD8-positive cells had an influence on the efficacy of immunotherapy.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Oncology
Yin Liu, Lei Fan, Zhong-Hua Wang, Zhi-Ming Shao
Summary: This study evaluated the efficacy and safety of nab-paclitaxel followed by dose-dense epirubicin/cyclophosphamide as neoadjuvant therapy in patients with triple-negative breast cancer, showing promising anti-tumor activity and acceptable tolerability.
Article
Chemistry, Multidisciplinary
Dengyuan Hao, Qian Meng, Chaonan Li, Shaojin Lu, Xiujuan Xiang, Qing Pei, Xiabin Jing, Zhigang Xie
Summary: Tuning the content of copper is highly significant for cancer and neurodegenerative disease treatment. A copper-chelating PTX prodrug was synthesized and could form stable nanoparticles in aqueous media. After internalization by tumor cells, the nanoparticles responded to redox-active species and released PTX, resulting in an enhanced therapeutic outcome for breast cancer with minimal systemic toxicity. This work provides insight into combining metabolic regulation and chemotherapy for malignant tumors.
Letter
Oncology
Shuling Chen, Jiaxin Li, Aoran Dong, Zelong Liu, Meiyan Zhu, Meng Jin, Guangyan Wei, Shuang Wu, Yan Wang, Yong Chen, Zhenwei Peng
Summary: This study compared the efficacy and safety of combination therapy with immunotherapy and radiotherapy versus chemotherapy alone for patients with locally advanced pancreatic adenocarcinoma (LAPC). The combination treatment group showed significant advantages in median overall survival and progression-free survival compared to the chemotherapy alone group. However, the incidence of severe adverse events did not differ significantly between the two groups. Therefore, combination therapy appears to be an effective and safe treatment option for LAPC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Oncology
Hanwen Wang, Huilin Ma, Richard J. Sove, Leisha A. Emens, Aleksander S. Popel
Summary: This study introduces a modular quantitative systems pharmacology (QSP) platform for predicting immunotherapy efficacy and identifying predictive biomarkers. Virtual clinical trials were conducted using a virtual patient cohort generated by the model, with retrospective analysis and model validation based on clinical trial data.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Li Chen, Yi-Zhou Jiang, Song-Yang Wu, Jiong Wu, Gen -Hong Di, Guang-Yu Liu, Ke-Da Yu, Lei Fan, Jun-Jie Li, Yi-Feng Hou, Zhen Hu, Can-Ming Chen, Xiao-Yan Huang, A-Yong Cao, Xin Hu, Shen Zhao, Xiao-Yan Ma, Ying Xu, Xiang-Jie Sun, Wen -Jun Chai, Xiaomao Guo, Xizi Chen, Yanhui Xu, Xiao-Yu Zhu, Jian-Jun Zou, Wen-Tao Yang, Zhong-Hua Wang, Zhi-Ming Shao
Summary: The novel combination of famitinib, camrelizumab, and nab-paclitaxel showed promising efficacy and safety in advanced immunomodulatory TNBC. The objective response rate was 81.3%, and the median PFS was 13.6 months.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Yuan Yuan, Jin Sun Lee, Susan E. Yost, Sierra Min Li, Paul H. Frankel, Christopher Ruel, Daniel Schmolze, Kim Robinson, Aileen Tang, Norma Martinez, Daphne Stewart, James Waisman, Laura Kruper, Veronica Jones, Andrea Menicucci, Sahra Uygun, Erin Yoder, Bastiaan van der Baan, John H. Yim, Christina Yeon, George Somlo, Joanne Mortimer
Summary: The combination of carboplatin and nab-paclitaxel showed manageable toxicity and encouraging antitumor activity in early stage high-risk triple-negative breast cancer. Immune-hot GSIS was associated with higher pCR rate and RCB class 0/1, providing rationale for future neoadjuvant trials in TNBC. Additional development of GSIS as a clinically applicable assay is indicated.
Article
Engineering, Biomedical
Beibei Guo, Yan Qu, Yinping Sun, Songsong Zhao, Jiandong Yuan, Peizhuo Zhang, Zhiyuan Zhong, Fenghua Meng
Summary: The combination of integrin-targeting micellar gemcitabine and paclitaxel (ATN-mG/P) with polymersomal CpG (NanoCpG) effectively heats up and treats TNBC, promoting anti-cancer immune responses.
BIOACTIVE MATERIALS
(2023)
Article
Oncology
Julia Foldi, Andrea Silber, Emily Reisenbichler, Kamaljeet Singh, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Nina Horowitz, Donald Lannin, Anees Chagpar, Tristen Park, Michal Marczyk, Courtney Frederick, Trisha Burrello, Eiman Ibrahim, Tao Qing, Yalai Bai, Kim Blenman, David L. Rimm, Lajos Pusztai
Summary: The Phase I/II trial aimed to evaluate the safety and efficacy of durvalumab in combination with other therapies for triple-negative breast cancer. The study found that the combination treatment resulted in a 44% pathologic complete response rate, with some patients experiencing grade 3/4 adverse events. Results suggest potential benefits of the combination therapy, particularly in patients with high stromal tumor-infiltrating lymphocytes.
Article
Oncology
Clinton Yam, Elizabeth A. Mittendorf, Haven R. Garber, Ryan Sun, Senthil Damodaran, Rashmi K. Murthy, David Ramirez, Meghan Karuturi, Rachel M. Layman, Nuhad Ibrahim, Gaiane M. Rauch, Beatriz E. Adrada, Rosalind P. Candelaria, Jason B. White, Elizabeth Ravenberg, Alyson Clayborn, Qing Qing Ding, W. Fraser Symmans, Sabitha Prabhakaran, Alastair M. Thompson, Vicente Valero, Debu Tripathy, Lei Huo, Stacy L. Moulder, Jennifer K. Litton
Summary: Neoadjuvant anti-PD-(L)1 therapy improves the pCR rate in unselected TNBC, but optimizing the risk-benefit ratio for these agents is important. This phase II study demonstrated a promising activity of atezolizumab and nab-paclitaxel as the second phase of NAT in AC-resistant TNBC, suggesting a response-adapted approach to neoadjuvant immunotherapy for further evaluation.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Peter A. Fasching, Alexander Hein, Hans-Christian Kolberg, Lothar Haeberle, Sabrina Uhrig, Matthias Ruebner, Erik Belleville, Carolin C. Hack, Tanja N. Fehm, Wolfang Janni, Arndt Hartmann, Ramona Erber, Anna-Katharin Theuser, Sara Y. Brucker, Andreas D. Hartkopf, Michael Untch
Summary: This study investigated the efficacy of nP-containing neoadjuvant chemotherapy in combination with pembrolizumab for breast cancer patients. The results showed a high pathological complete response rate and acceptable side effects.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Genta Ito, Kazuyoshi Kawakami, Takeshi Aoyama, Takashi Yokokawa, Masashi Nakamura, Masato Ozaka, Naoki Sasahira, Masayuki Hashiguchi, Hayato Kizaki, Toshihiro Hama, Satoko Hori
Summary: Combination therapy with gemcitabine and nanoparticle albumin-bound paclitaxel (GnP therapy) can significantly prolong the survival of pancreatic cancer patients but may also lead to severe neutropenia. This study identified low ANC, high T-Bil, and low CRP as risk factors for Grade 3/4 neutropenia during GnP therapy. Patients with these risk factors should be closely monitored for adverse events.
Article
Oncology
Sibylle Loibl, Delphine Loirat, Sara M. Tolaney, Kevin Punie, Mafalda Oliveira, Hope S. Rugo, Aditya Bardia, Sara A. Hurvitz, Adam M. Brufsky, Kevin Kalinsky, Javier Cortes, Joyce A. O'Shaughnessy, Veronique Dieras, Lisa A. Carey, Luca Gianni, Mahdi Gharaibeh, Luciana Preger, See Phan, Lawrence Chang, Ling Shi, Martine J. Piccart
Summary: This study investigated the effect of the antibody-drug conjugate sacituzumab govitecan (SG) on the health-related quality of life (HRQoL) in patients with metastatic triple-negative breast cancer (mTNBC). The results showed that SG was associated with greater improvements and delayed worsening of HRQoL scores compared with other treatment options chosen by physicians.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stephane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Munoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis De La Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina Long
Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, A. Jo Chien, Hope S. Rugo, Adam Brufsky, Michael Thirlwell, Maureen Trudeau, Ron Bose, Jose A. Garcia-Saenz, Daniel Egle, Barbara Pistilli, Johanna Wassermann, Kerry A. Cheong, Benjamin Schnappauf, Dieter Semsek, Christian F. Singer, Navid Foruzan, Daniel DiPrimeo, Leanna McCullouch, Sara A. Hurvitz, Carlos H. Barcenas
Summary: This study investigated two strategies for preventing diarrhea caused by the pan-HER tyrosine kinase inhibitor Neratinib. The results showed that Neratinib can reduce the incidence of diarrhea and early discontinuation, and more patients were able to use Neratinib for the prescribed period compared to historical controls.
Article
Oncology
Teresa Hagan Thomas, Patty Jo Murray, Margaret Rosenzweig, Sarah Taylor, Adam Brufsky, Catherine Bender, Mikayla Larkin, Yael Schenker
Summary: This study describes a novel self-advocacy serious game intervention called "Strong Together" and evaluates its effectiveness through participant perspectives. The results suggest that participants had a positive attitude towards the intervention, stating that it reflected their personal experiences in realistic scenarios. Participants recommended adding diverse characters to the game.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Priya Rastogi, Gong Tang, Saima Hassan, Charles E. Geyer Jr, Catherine A. Azar, Gustav C. Magrinat, J. Marie Suga, Harry D. Bear, Luis Baez-Diaz, Shakir Sarwar, Jean-Francois Boileau, Adam M. Brufsky, Henry R. Shibata, Hanna Bandos, Soonmyung Paik, Greg Yothers, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark
Summary: This study aimed to compare the efficacy of trastuzumab alone or in combination with lapatinib in treating HER2-positive breast cancer patients. The results showed that although the combination therapy and the use of lapatinib had better outcomes, the differences were not statistically significant. However, achieving pathological complete response correlated with improved prognosis, especially in the ER-negative subset.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Teresa Hagan Thomas, Catherine Bender, Heidi S. S. Donovan, Patty Jo Murray, Sarah Taylor, Margaret Rosenzweig, Susan M. M. Sereika, Adam Brufsky, Yael Schenker
Summary: This study examines the feasibility, acceptability, and preliminary efficacy of a self-advocacy serious game intervention in women with advanced breast or gynecologic cancer. The results demonstrate that the intervention is feasible, acceptable, and effective among these patients.
Review
Oncology
Hope S. Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Massimo Cristofanilli, Mylin A. Torres, Giuseppe Curigliano, Richard S. Finn, Angela DeMichele
Summary: This is a summary of an article about a study called P-REALITY X, which found that patients with metastatic HR+/HER2- breast cancer treated with palbociclib plus an AI lived longer than those treated with an AI only in routine clinical practice. These results support the use of palbociclib plus an AI as the standard first-line treatment for this type of breast cancer.
Editorial Material
Oncology
Adam Brufsky, Christopher Gallagher
Summary: Stringent enrollment criteria in clinical trials may limit patient diversity and hinder the generalizability of trial data. Real-world data from the P-REALITY X study provide evidence supporting the use of palbociclib plus an aromatase inhibitor as a first-line treatment for HR+/HER2- metastatic breast cancer patients. The study observed significant benefits in overall survival and real-world progression-free survival when compared to an aromatase inhibitor alone, across various patient subgroups.
Article
Oncology
Julia Foldi, Anastasia Tsagianni, Max Salganik, Catherine A. Schnabel, Adam Brufsky, G. J. van Londen, Lajos Pusztai, Tara Sanft
Summary: Extending adjuvant endocrine therapy beyond the standard 5 years can protect against late breast cancer recurrences. This study evaluated persistence to extended therapy in women who had Breast Cancer Index testing, and found high rates of persistence in patients with predicted high likelihood of benefit.
Article
Biochemistry & Molecular Biology
Marylene Lejeune, Laia Reverte, Noelia Gallardo, Esther Sauras, Ramon Bosch, Daniel Mata, Albert Roso, Anna Petit, Vicente Peg, Francisco Riu, Joan Garcia-Fontgivell, Fernanda Relea, Begona Vieites, Luis de la Cruz-merino, Meritxell Arenas, Valeri Rodriguez, Juana Galera, Anna Korzynska, Benoit Plancoulaine, Tomas Alvaro, Carlos Lopez
Summary: This study characterized the residual tumor microenvironment in 96 TNBC patients and evaluated its prognostic implications for partial responders vs. non-responders. Partial responders showed higher levels of CD83+ mature dendritic cells, FOXP3+ regulatory T cells, and IL-15 expression but lower CD138+ cell concentration, leading to improved overall survival and recurrence-free survival. However, MMP-9 expression in the residual tumor microenvironment was identified as an independent factor associated with the impaired response to neoadjuvant chemotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Hope S. Rugo, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Adam Brufsky
Summary: The study demonstrates that the combination of palbociclib and an aromatase inhibitor is effective in treating first-line HR+/HER2- metastatic breast cancer in African American patients.
Article
Oncology
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn Mcroy, Connie Chen, Rachel M. Layman, Hope S. Rugo
Summary: A retrospective study showed that the combination of cyclin-dependent kinase 4/6 inhibitor and endocrine therapy was associated with prolonged overall survival and real-world progression-free survival in patients with hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer with lung and/or liver metastases.
Article
Oncology
Susrutha Puthanmadhom Narayanan, Dianxu Ren, Steffi Oesterreich, Adrian V. Lee, Margaret Q. Rosenzweig, Adam M. Brufsky
Summary: Race and socioeconomic factors have an impact on overall survival and treatment patterns in patients with metastatic breast cancer (MBC). Low neighborhood socioeconomic status is associated with worse outcomes in MBC patients, and the poor outcomes in Black patients with MBC are at least partly driven by socioeconomic factors.
Meeting Abstract
Oncology
Stephanie (Smith) Reyes, Adam Brufsky, Jocelyn Timko, Linda Gracie-King, Victor Ocana, Dee Morgillo
ONCOLOGY NURSING FORUM
(2023)
Review
Biochemistry & Molecular Biology
Maria Luisa Sanchez-Leon, Carlos Jimenez-Cortegana, Silvia Silva Romeiro, Carmen Garnacho, Luis de la Cruz-Merino, Daniel J. Garcia-Dominguez, Lourdes Hontecillas-Prieto, Victor Sanchez-Margalet
Summary: Breast cancer is the most diagnosed tumor in women with diverse molecular profiles. Despite the advancements in early detection and therapy, patients with metastatic disease have low survival rates. Immunotherapy, due to its ability to modulate the immune system, has emerged as a promising alternative. This review focuses on the new immunotherapies in breast cancer in the last five years and discusses the role of myeloid-derived suppressor cells as a therapeutic target.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)